{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360574094762954752.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00535-004-1430-x"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-004-1430-x.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00535-004-1430-x/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00535-004-1430-x"}},{"identifier":{"@type":"PMID","@value":"15549461"}}],"dc:title":[{"@value":"Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan"}],"description":[{"notation":[{"@value":"In Japan, there are few studies of long-term (more than 1 month) interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy and predictors of response to 6-month IFN therapy.We analyzed 66 Japanese patients with CHB who were treated with IFN for 6 months. They comprised patients who were hepatitis B e antigen (HBeAg)-positive (n=45) and -negative (n=21). One (2%), 8 (12%), and 51 (77%) patients were infected with hepatitis B virus (HBV) genotypes A, B, and C, respectively. Responders in patients positive for HBeAg were defined as those who showed normalization of serum alanine aminotransferase (ALT) level, HBeAg loss, and HBV DNA negativity at 6 months after completion of IFN therapy. In patients negative for HBeAg, responders were defined as those patients who showed normalization of ALT level and HBV DNA negativity at the same 6-month time point.Of the 45 patients with HBeAg at the commencement of IFN therapy, 9 (20%) were responders. Young patients, especially those with a high serum ALT level, were significantly more likely to respond to IFN therapy. Of the 21 patients negative for HBeAg, 13 (62%) were responders. There were no significant differences in clinical characteristics between responders and nonresponders among patients negative for HBeAg. Multivariate analyses identified HBeAg negativity and young age as independent factors associated with a positive response to 6-month IFN therapy. However, long-term follow-up of the treated patients showed a fall in the response rate.The response rate to 6-month IFN therapy among HBeAg-positive patients was low. However, young patients may require long-term IFN therapy."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380574094762954754","@type":"Researcher","foaf:name":[{"@value":"Fumitaka Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954759","@type":"Researcher","foaf:name":[{"@value":"Yasuji Arase"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954753","@type":"Researcher","foaf:name":[{"@value":"Norio Akuta"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954757","@type":"Researcher","foaf:name":[{"@value":"Akihito Tsubota"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954755","@type":"Researcher","foaf:name":[{"@value":"Yoshiyuki Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954760","@type":"Researcher","foaf:name":[{"@value":"Hitomi Sezaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954756","@type":"Researcher","foaf:name":[{"@value":"Tetsuya Hosaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954628","@type":"Researcher","foaf:name":[{"@value":"Takashi Someya"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954758","@type":"Researcher","foaf:name":[{"@value":"Masahiro Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954625","@type":"Researcher","foaf:name":[{"@value":"Satoshi Saitoh"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954752","@type":"Researcher","foaf:name":[{"@value":"Kenji Ikeda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954626","@type":"Researcher","foaf:name":[{"@value":"Mariko Kobayashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954624","@type":"Researcher","foaf:name":[{"@value":"Marie Matsuda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954627","@type":"Researcher","foaf:name":[{"@value":"Junko Satoh"}]},{"@id":"https://cir.nii.ac.jp/crid/1380574094762954629","@type":"Researcher","foaf:name":[{"@value":"Hiromitsu Kumada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09441174"},{"@type":"EISSN","@value":"14355922"}],"prism:publicationName":[{"@value":"Journal of Gastroenterology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2004-10","prism:volume":"39","prism:number":"10","prism:startingPage":"969","prism:endingPage":"974"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-004-1430-x.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00535-004-1430-x/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00535-004-1430-x"}],"createdAt":"2004-11-03","modifiedAt":"2019-05-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Gastroenterology","dc:title":"Gastroenterology"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714657048832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185916732416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00535-004-1430-x"},{"@type":"OPENAIRE","@value":"doi_dedup___::0aa40980d49bf13f0d2e2b7114b33601"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.1128/aac.00183-17_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.3851/imp3225_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_2iUeSJXSlLvkSU3JzsNi3aXtDwm"}]}